Loading...
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2 diabetes. This compound improves insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator-activated receptor-γ (PPAR-γ). In addition to sensitizing cells to insulin, the PPAR-γ2 is...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2003
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1855213/ https://ncbi.nlm.nih.gov/pubmed/14500573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2003-0746 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|